keyword
https://read.qxmd.com/read/38465548/epidemiological-trends-in-cutaneous-lymphomas-in-greece
#21
JOURNAL ARTICLE
Stella Kaliampou, Vasiliki Nikolaou, Aikaterini Niforou, Ioanna Kotsiopoulou, Maria Gerochristou, Asimina Papanikolaou, Georgios Kanellis, Evangelia Papadavid, Antonios Tsimpidakis, Evdoxia Pouliou, Elisavet Economaki, Evdoxia Panou, Christos Nikolaou, Alexander J Stratigos, Androniki Naska, Leonidas Marinos
Primary cutaneous lymphomas (PCLs) are a heterogenous group of non-Hodgkin lymphomas arising in the skin from T- or B-lymphocytes, for which there is limited epidemiological data available. To describe the disease characteristics and estimate annual incidence rates (IRs) and temporal trends of PCLs and their subtypes in Attica, Greece. A retrospective analysis of all PCL patients, diagnosed in Attica's main haemopathology referral centre from 2009 to 2021, was conducted. In total, 1,189 patients were included; 725 males and 464 females (males__females=1...
December 1, 2023: European Journal of Dermatology: EJD
https://read.qxmd.com/read/38465544/pigmented-purpura-dermatosis-like-mycosis-fungoides-four-case-reports-and-a-review-of-published-cases
#22
REVIEW
Jingru Sun, Kecen Liu, Jingyang Dang, Shan Xiong, Haihao Pan, Yang Wang
Mycosis fungoides (MF) is the most prevalent type of cutaneous T-cell lymphoma and is generally characterized by multiple patches or plaques with fine scales. One of its variants manifests with multiple purpuric eruptions, mimicking benign pigmented purpuric dermatosis (PPD). To investigate clinicopathological features of PPD-like MF patients. We report four PPD-like MF cases and summarize the clinicopathological features described in reports of nine PPD-like MF cases published in the past 20 years. Compared with benign PPD, petechial lesions in PPD-like MF are more generalized, persistent, and resistant to conventional steroid treatment...
December 1, 2023: European Journal of Dermatology: EJD
https://read.qxmd.com/read/38457671/febrile-ulceronecrotic-mucha-habermann-disease-associated-with-hemophagocytic-lymphohistiocytosis-a-case-report-and-review-of-the-literature
#23
JOURNAL ARTICLE
Caroline Chen, Lauren M Fahmy, Celine M Schreidah, Cynthia M Magro, Larisa J Geskin
Mucha-Habermann disease (MHD) is an inflammatory skin disease characterized by polymorphous eruptions of erythematous, necrotic macules that have been reported for similarities to cutaneous T-cell lymphoma. Febrile ulceronecrotic MHD (FUMHD) represents a severe variant of MHD, marked by ulcers, hemorrhagic bullae, and systemic symptoms. Herein, we report a case of a severely atypical lymphomatoid expression of FUMHD associated with hemophagocytic lymphohistiocytosis (HLH). A previously healthy 21-year-old woman was admitted to the hospital with a rapidly progressive necrotic papular rash...
April 1, 2024: American Journal of Dermatopathology
https://read.qxmd.com/read/38456078/an-occurrence-of-eosinophilic-folliculitis-and-alopecia-associated-with-a-sustained-complete-response-to-mogamulizumab-in-s%C3%A3-zary-syndrome-a-case-report
#24
Jean-Matthieu L'Orphelin
Mogamulizumab is a monoclonal antibody that binds to C-C chemokine receptor 4 (CCR4), initiating antibody-dependent cellular cytotoxicity. CCR4 is highly expressed in the cutaneous T-cell lymphoma subtypes mycosis fungoides and Sézary syndrome (SS), and mogamulizumab has been shown to be effective in patients with these conditions who were refractory to at least one prior systemic treatment. One of the more common adverse events encountered with mogamulizumab is rash, which may mimic disease progression and lead to premature discontinuation...
2024: Therapeutic Advances in Hematology
https://read.qxmd.com/read/38451372/update-on-t-cell-lymphoma-epidemiology
#25
REVIEW
Jane J Chen, Franco Castillo Tokumori, Christina Del Guzzo, Jeanyoung Kim, Jia Ruan
PURPOSE OF REVIEW: T-cell lymphomas (TCLs) are a group of rare subtypes of non-Hodgkin lymphoma derived from mature T-lymphocytes. Recent updates in lymphoma classification based on the cell-of-origin pathogenesis have shed new light on TCL epidemiology and outcomes. Contemporary regional consortia and international studies, including those conducted recently in Asia and South America, have provided an updated delineation of the major subtypes across various global regions. RECENT FINDINGS: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), remains the most common subtype globally except in Asia, where extra-nodal NK-T cell lymphoma (ENKTL) has emerged as the most prevalent...
March 7, 2024: Current Hematologic Malignancy Reports
https://read.qxmd.com/read/38450476/immunobiology-and-treatment-of-cutaneous-t-cell-lymphoma
#26
REVIEW
Rishi R Goel, Alain H Rook
INTRODUCTION: Primary cutaneous T cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas derived from skin-homing T cells. These include mycosis fungoides and its leukemic variant Sezary syndrome, as well as the CD30+ lymphoproliferative disorders. AREAS COVERED: In this review, we provide a summary of the current literature on CTCL, with a focus on the immunopathogenesis and treatment of mycosis fungoides and Sezary syndrome. EXPERT OPINION: Recent advances in immunology have provided new insights into the biology of malignant T cells...
March 7, 2024: Expert Review of Clinical Immunology
https://read.qxmd.com/read/38449891/an-unusual-presentation-of-subcutaneous-panniculitis-like-t-cell-lymphoma-extensive-necrosis-and-hemophagocytic-lymphohistiocytosis-a-case-report
#27
Mehdi Loukhnati, Khaoula Khalil, Fatima Ezzahra Lahlimi, Illias Tazi
KEY CLINICAL MESSAGE: Subcutaneous panniculitis-like T-cell lymphoma, a primary cutaneous lymphoma, which is described as following a slow course, could claim life. The occurrence of facial and breast nodules, the association with hemophagocytic lymphohistiocytosis, and the extent of necrosis and ulceration are signs of its aggressive nature needing early diagnosis and prompt treatment. ABSTRACT: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare skin disease that accounts for <1% of all peripheral T-cell lymphomas...
March 2024: Clinical Case Reports
https://read.qxmd.com/read/38444271/evaluation-of-mortality-prognostic-parameters-and-treatment-efficacy-in-mycosis-fungoides
#28
JOURNAL ARTICLE
Stefanie Porkert, Johannes Griss, Mercedes Hudelist-Venz, Irene Steiner, Julia Valencak, Wolfgang Weninger, Patrick M Brunner, Constanze Jonak
BACKGROUND AND OBJECTIVES: Mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, is characterized by a variable clinical course, presenting either as indolent disease or showing fatal progression due to extracutaneous involvement. Importantly, the lack of prognostic models and predominantly palliative therapy settings hamper patient care. Here, we aimed to define survival rates, disease prediction accuracy, and treatment impact in MF. PATIENTS AND METHODS: Hundred-forty MF patients were assessed retrospectively...
March 5, 2024: Journal der Deutschen Dermatologischen Gesellschaft: JDDG
https://read.qxmd.com/read/38436589/predictive-and-prognostic-biomarkers-in-patients-with-mycosis-fungoides-and-s%C3%A3-zary-syndrome-bio-muse-study-protocol-for-a-translational-study
#29
JOURNAL ARTICLE
Emma Belfrage, Sara Ek, Åsa Johansson, Hanna Brauner, Andreas Sonesson, Kristina Drott
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) is a rare group of lymphomas that primarily affects the skin. Mycosis fungoides (MF) is the most common form of CTCL and Sézary syndrome (SS) is more infrequent. Early stages (IA-IIA) have a favorable prognosis, while advanced stages (IIB-IVB) have a worse prognosis. Around 25% of patients with early stages of disease will progress to advanced stages. Malignant skin-infiltrating T-cells in CTCL are accompanied by infiltrates of non-malignant T-cells and other immune cells that produce cytokines that modulate the inflammation...
February 9, 2024: JMIR Research Protocols
https://read.qxmd.com/read/38435536/cutaneous-t-cell-lymphoma-and-microbiota-etiopathogenesis-and-potential-new-therapeutic-targets
#30
REVIEW
Daniel Rodríguez Baeza, Lía Bejarano Antonio, Marta González de Arriba, José Antonio Picó-Monllor, Javier Cañueto, Vicente Navarro-Lopez
OBJECTIVE: To review the scientific literature related to human microbiota and cutaneous T-cell lymphoma. Methodology . An exploratory and systematic review of the articles retrieved from the bibliographic databases MEDLINE (PubMed), Embase, The Cochrane Library, and Scopus, published in the last 10 years with the following descriptors: "lymphoma, T-cell, cutaneous," "microbiota," "Mycosis Fungoides," "Sézary Syndrome," "lymphoma, primary cutaneous anaplastic large cell," "Lymphomatoid Papulosis" and "Microbiota," "microbiota," "Microbial Community," and "Microbial Communities...
2024: Dermatology Research and Practice
https://read.qxmd.com/read/38434474/primary-cutaneous-gamma-delta-t-cell-lymphoma-simulating-lupus-erythematosus-panniculitis-what-do-we-know-about-this-aggressive-mimicker
#31
JOURNAL ARTICLE
Francisco J D Torre-Gomar, Javier Gimeno-Castillo, Amaia Sagasta-Lacalle, Itziar Arrue-Michelena
No abstract text is available yet for this article.
February 2024: Sultan Qaboos University Medical Journal
https://read.qxmd.com/read/38422999/early-organ-metastasis-in-granulomatous-mycosis-fungoides-a-systematic-review
#32
Melika Motamedi, Maggie Zx Xiao, Jean Deschenes, Jori Hardin, Russell Sterrett, Lesley Street, Minakshi Taparia, Etienne Mahe, Giovanni Ferrara, James R Barrie, Robert Gniadecki
BACKGROUND: Granulomatous mycosis fungoides (GMF) is a rare form of cutaneous T-cell lymphoma characterized by a granulomatous inflammatory infiltrate. OBJECTIVE: The impact of granulomatous inflammation on the prognosis of the disease remains controversial as there are both favorable and unfavorable outcomes documented. METHODS: We performed a systematic review of 116 GMF cases previously described in the literature. RESULTS: In contrast to the classic Alibert-Bazin type of mycosis fungoides (MF), cutaneous lesions in GMF tend to involve distal extremities (lower legs, feet, hands) early in the disease course...
February 29, 2024: Dermatology: International Journal for Clinical and Investigative Dermatology
https://read.qxmd.com/read/38419393/safety-and-effectiveness-of-the-combination-of-systemic-gemcitabine-and-intralesional-brentuximab-vedotin-in-tumor-stage-mycosis-fungoides
#33
JOURNAL ARTICLE
Juan Torre-Castro, Miguel Recio-Monescillo, Eva Castillo Bazan, Javier Díaz de la Pinta, María Rodríguez Pinilla, Luis Requena, Raul Córdoba
No abstract text is available yet for this article.
February 28, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38419370/stenotrophomonas-maltophilia-skin-infection-in-an-immunocompetent-patient-primary-cutaneous-cd30-t-cell-lymphoproliferative-disorder-or-pseudolymphoma
#34
Monia Di Prete, Alessandra Scarabello, Viviana Lora, Carlo Cota
Cutaneous pseudolymphomas are a wide group of diseases mimicking cutaneous lymphoma. They comprise several skin conditions with different etiopathogenesis, clinical-pathological features, and prognosis, which may occur in the absence of an identifiable trigger factor or after administration of medications or vaccinations, tattoos, infections, or arthropod bites. They present with different manifestations: from solitary to regionally clustered lesions, up to generalized distribution and, in rare cases, erythroderma...
February 28, 2024: Journal of Cutaneous Pathology
https://read.qxmd.com/read/38417247/spindle-cell-cutaneous-epitheliotropic-t-cell-lymphoma-in-an-american-bulldog
#35
JOURNAL ARTICLE
Alexis Carpenter, Kimberly Aeschlimann, Keiichi Kuroki
An 8-year-old American Bulldog developed coalescing exophytic bulbous nodules that grew rapidly on the left pinna and a single cutaneous mass on the left flank. Histological examination of the pinnal biopsy by a diagnostic laboratory revealed a densely cellular neoplasm with haphazardly arranged round to spindle cells with high mitotic activity and epitheliotropism. The initial diagnosis was a poorly differentiated malignant neoplasm with differential diagnoses including melanoma, tumour of histiocytic origin and, less likely, a pleomorphic lymphoma...
February 27, 2024: Journal of Comparative Pathology
https://read.qxmd.com/read/38416722/the-effect-of-uva-light-8-methoxypsoralen-exposure-used-in-extracorporeal-photopheresis-treatment-on-platelets-and-extracellular-vesicles
#36
JOURNAL ARTICLE
Hayley Macleod, Luisa Weiss, Sarah Kelliher, Barry Kevane, Fionnuala Ní Áinle, Patricia B Maguire
Extracorporeal Photopheresis (ECP) is a leukapheresis based treatment for Cutaneous T-Cell Lymphoma, which takes advantage of the cellular lethal effects of UVA light in combination with a photoactivated drug, 8-methoxypsoralen. 25% of patients treated with ECP do not respond to treatment, however the underlying mechanisms for this lack of response remain unknown. Platelets, a rich source of extracellular vesicles (EVs) and key mediators in thromboinflammatory oncological progression, as well as leukocytes, are both processed through ECP and are subsequently transfused back into the patient, delivering potent immunomodulation...
2024: PloS One
https://read.qxmd.com/read/38415859/antibody-targeting-of-surface-p-selectin-glycoprotein-ligand-1-leads-to-lymphoma-apoptosis-and-tumorigenesis-inhibition
#37
JOURNAL ARTICLE
João L Pereira, Francisca Ferreira, Nuno R Dos Santos
Lymphomas are a heterogeneous group of diseases that originate from T, B or natural killer cells. Lymphoma treatment is based on chemotherapy, radiotherapy, and monoclonal antibody (mAb) or other immunotherapies. The P-selectin glycoprotein ligand 1 (PSGL-1) is expressed at the surface of hematological malignant cells and has been shown to have a pro-oncogenic role in multiple myeloma and lymphoma. Here, we investigated the expression and therapeutic potential of PSGL-1 in T and B cell lymphomas. By flow cytometry analysis, we found that PSGL-1 was expressed in both T and B cell-derived lymphoma cell lines but generally at higher levels in T cell lymphoma cell lines...
March 2024: Hematological Oncology
https://read.qxmd.com/read/38410820/phenotypic-spectrum-in-a-family-with-a-novel-rac2-p-i21s-dominant-activating-mutation
#38
Louisa Ashby, Lydia Chan, Christine Winterbourn, See-Tarn Woon, Paula Keating, Raoul Heller, Rohan Ameratunga, Ignatius Chua, Kuang-Chih Hsiao
OBJECTIVES: Dominant-activating (DA) lesions in RAC2 have been reported in 18 individuals to date. Some have required haematopoietic stem cell transplantation (HSCT) for their (severe) combined immunodeficiency syndrome phenotype. We aimed to investigate clinical and cellular features of a kindred harbouring a novel variant in RAC2 p.Ile21Ser (I21S) to better understand DA lesions' phenotypic spectrum. METHODS: Clinical and immunological information was collated for seven living individuals from the same kindred with RAC2 p...
2024: Clinical & Translational Immunology
https://read.qxmd.com/read/38398754/role-of-il-4-and-il-13-in-cutaneous-t-cell-lymphoma
#39
REVIEW
Roberto Mazzetto, Paola Miceli, Jacopo Tartaglia, Christian Ciolfi, Alvise Sernicola, Mauro Alaibac
The interleukins IL-4 and IL-13 are increasingly recognized contributors to the pathogenesis of cutaneous T cell lymphomas (CTCLs), and their role in disease-associated pruritus is accepted. The prevailing Th2 profile in advanced CTCL underscores the significance of understanding IL-4/IL-13 expression dynamics from the early stages of disease, as a shift from Th1 to Th2 may explain CTCL progression. Targeted agents blocking key cytokines of type 2 immunity are established therapeutics in atopic disorders and have a promising therapeutic potential in CTCL, given their involvement in cutaneous symptoms and their contribution to the pathogenesis of disease...
February 9, 2024: Life
https://read.qxmd.com/read/38396877/clinical-and-real-world-effectiveness-of-mogamulizumab-a-narrative-review
#40
REVIEW
Montserrat Fernández-Guarino, Pablo Ortiz, Fernando Gallardo, Mar Llamas-Velasco
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and Sézary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing positive outcomes...
February 12, 2024: International Journal of Molecular Sciences
keyword
keyword
6668
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.